Lantheus (LNTH) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Lantheus will report Q1 2026 results before the market opens on May 7; analysts expect EPS of $1.26 and revenue of about $354.9M, and the company has set FY 2026 guidance of $5.00–$5.25 EPS.
• The company beat the prior quarter with $1.67 EPS (vs. $1.17 expected) and $406.8M revenue, while analysts project roughly $4 EPS for the current fiscal year and $5 EPS for the next.
• Shares have a market cap of $5.28B, a P/E around 24, a 52-week range of $47.25–$108.91, and a consensus rating of Moderate Buy with a $88.86 target amid several recent analyst price-target increases (Jefferies $110).

Lantheus (NASDAQ:LNTH - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of $1.26 per share and revenue of $354.8690 million for the quarter. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The firm had revenue of $406.79 million for the quarter, compared to analysts' expectations of $367.03 million. During the same period in the previous year, the firm posted $1.59 EPS. The business's revenue for the quarter was up 4.0% compared to the same quarter last year. On average, analysts expect Lantheus to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Lantheus Stock Performance

Shares of LNTH opened at $81.17 on Thursday. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The business's 50 day moving average price is $78.62 and its 200-day moving average price is $67.91. Lantheus has a 52 week low of $47.25 and a 52 week high of $108.91. The stock has a market cap of $5.28 billion, a P/E ratio of 24.09 and a beta of -0.12.

Hedge Funds Weigh In On Lantheus

A number of hedge funds have recently added to or reduced their stakes in LNTH. EverSource Wealth Advisors LLC raised its holdings in Lantheus by 190.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider's stock worth $87,000 after acquiring an additional 698 shares during the last quarter. First Trust Advisors LP raised its holdings in Lantheus by 37.4% in the 2nd quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider's stock worth $5,714,000 after acquiring an additional 19,008 shares during the last quarter. Baird Financial Group Inc. raised its holdings in Lantheus by 22.6% in the 2nd quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider's stock worth $222,000 after acquiring an additional 500 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in Lantheus by 88.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider's stock worth $278,000 after acquiring an additional 1,591 shares during the last quarter. Finally, Osterweis Capital Management Inc. purchased a new position in Lantheus in the 2nd quarter worth approximately $36,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LNTH has been the topic of a number of analyst reports. Citizens Jmp boosted their price target on Lantheus from $73.00 to $78.00 and gave the stock a "market outperform" rating in a research report on Tuesday, February 24th. Truist Financial boosted their price target on Lantheus from $89.00 to $98.00 and gave the stock a "buy" rating in a research report on Wednesday, April 15th. William Blair reissued an "outperform" rating on shares of Lantheus in a research report on Tuesday, March 17th. Wall Street Zen raised Lantheus from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 28th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $110.00 price target on shares of Lantheus in a research report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $88.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.